Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.51 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.42 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.42 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110802 | 0.89 | TRPV1 (0.60) | TRPV1PIP4K2APIP4K2C | |
| SCHEMBL5116582 | 0.86 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL4009599 | 0.86 | TRPV1 (0.69) | TRPV1PIP5K1CPIP4K2APIP4K2C | |
| SCHEMBL5110249 | 0.85 | TRPV1 (0.50) | TRPV1KDR | |
| SCHEMBL5111701 | 0.85 | TRPV1 (0.55) | TRPV1KDR | |
| SCHEMBL5102915 | 0.84 | TRPV1 (0.48) | TRPV1KDR | |
| SCHEMBL5109594 | 0.84 | TRPV1 (0.48) | TRPV1PIP4K2AKDR | |
| SCHEMBL5111752 | 0.83 | TRPV1 (0.55) | TRPV1PIP4K2A | |
| SCHEMBL5109766 | 0.82 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL14289570 | 0.82 | TRPV1 (0.61) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | claimed |
| WO-2008005303-A2 | THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004253-A1 | Thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885PIP5K1C 1232/4885PIP4K2A 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.